|
1
|
Dome JS and Huff V: Wilms Tumor Overview.
GeneReviews. Pagon RA, Bird TD, Dolan CB and Stephans K: University
of Washington; Seattle: 2011
|
|
2
|
Rivera MN, Kim WJ, Wells J, et al: An X
chromosome gene, WTX, is commonly inactivated in Wilms tumor.
Science. 315:642–645. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Haber DA, Sohn RL, Buckler AJ, Pelletier
J, Call KM and Housman DE: Alternative splicing and genomic
structure of the Wilms tumor gene WT1. Proc Natl Acad Sci.
88:9618–9622. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lamond AI: RNA processing. Wilms’ tumour -
the splicing connection? Curr Biol. 5:862–865. 1995.
|
|
5
|
Wells J, Rivera MN, Kim WJ, Starbuck K and
Haber DA: The predominant WT1 isoform (+KTS) encodes a DNA
binding protein targeting the planar cell polarity gene
Scribble in renal podocytes. Mol Cancer Res. 8:975–985.
2010.
|
|
6
|
Huff V: Wilms’ tumours: about tumour
suppressor genes, an oncogene and a chameleon gene. Nature.
11:111–121. 2011.
|
|
7
|
Pelletier J, Bruening W, Kashtan CE, et
al: Germline mutations in the Wilms’ tumor suppressor gene are
associated with abnormal urogenital development in Denys-Drash
syndrome. Cell. 67:437–447. 1991.
|
|
8
|
Koesters R, Ridder R, Kopp-Schneider AK,
et al: Mutational activation of the β-catenin proto-oncogene is a
common event in the development of Wilms’ tumors. J Cancer Res.
59:3880–3882. 1999.
|
|
9
|
Maeda O, Usami N, Kondo M, et al:
Plakoglobin (γ-catenin) has TCF/LEF family - dependent
transcriptional activity in beta-catenin-deficient cell line.
Oncogene. 23:964–972. 2004.
|
|
10
|
Oloumi A, McPhee T and Dedhar S:
Regulation of E-cadherin expression and beta-catenin/Tcf
transcriptional activity by the integrin-linked kinase. Biochim
Biophys Acta. 1691:1–15. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Major MB, Camp ND, Berndt JD, et al: Wilms
tumor supressor WTX negatively regulates Wnt/β-catenin signaling.
Science. 316:1043–1046. 2007.
|
|
13
|
Rivera MN, Kim WJ, Wells J, Stone A, et
al: The tumor suppressor WTX shuttles to the nucleus and modulates
WT1 activity. Proc Natl Acad Sci USA. 106:8338–8343. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Miller SA, Dykes DD and Polesky HF: A
simple salting out procedure for extracting DNA from human
nucleated cells. Nucleic Acids Res. 16:12151988. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sambrook J, Fritsch EF and Maniatis T:
Molecular Cloning: A Laboratory Manual. 2nd edition. Cold Spring
Harbor; New York: 1989
|
|
16
|
Nacional Center for Biotechnology
Information. http://www.ncbi.nlm.nih.gov/:.
Accessed April 14, 2012
|
|
17
|
Milani L, Gupta M, Andersen M, et al:
Allelic imbalance in gene expression as a guide to cis-acting
regulatory single nucleotide polymorphisms in cancer cells. Nucleic
Acids Res. 35:e34–e43. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ho PA, Kuhn J, Gerbing RB, et al: WT1
synonymous single nucleotide polymorphism rs16754 correlates with
higher mRNA expression and predicts significantly improved outcome
in favorable-risk pediatric acute myeloid leukemia: a report from
the children’s oncology group. J Clin Oncol. 29:704–711.
2011.PubMed/NCBI
|
|
19
|
Splice-Site Analyzer Tool. Genome
Bioinformatics group of University of California Santa Cruz:
Splice-Site analyzer tool. http://ibis.tau.ac.il/ssat/SpliceSiteFrame.htm.
Accessed January 20, 2012
|
|
20
|
Royer-Pokora B, Beier M, Henzler M, Alan
R, Schumacher V, Weirich A and Huff V: Twenty-four new cases of
WT1 germline mutations and review of the literature:
genotype/phenotype correlations for Wilms tumor development. Am J
Med Genet A. 127:249–257. 2004.
|
|
21
|
Kohsaka T, Tagawa M, Takekoshi Y,
Yanagisawa H, Tadokoro K and Yamada M: Exon 9 mutations in the
WT1 gene, without influencing KTS splice isoforms, are also
responsible for Frasier syndrome. Hum Mutat. 14:466–470.
1999.PubMed/NCBI
|
|
22
|
Little MH, Prosser J, Condie A, Smith PJ,
Van Heyningen V and Hastie ND: Zinc finger point mutations within
the WT1 gene in Wilms tumor patients. Proc Natl Acad Sci USA.
89:4791–4795. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schumacher V, Schneider S, Figge A, et al:
Correlation of germ-line mutations and two-hit inactivation of the
WT1 gene with Wilms tumors of stromal-predominant histology.
Proc Natl Acad Sci USA. 94:3972–3977. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Maiti S, Alam R, Amos CI and Huff V:
Frequent association of β-catenin and WT1 mutations in Wilms
tumors. Cancer Res. 60:6288–6292. 2000.
|
|
25
|
Shibata R, Hashiguchi A, Sakamoto J,
Yamada T, Umezawa A and Hata J: Correlation between a specific
Wilms tumour suppressor gene (WT1) mutation and the
histological findings in Wilms tumour (WT). J Med Genet.
39:e832002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Little SE, Hanks SP, King-Underwood L, et
al: Frequency and heritability of WT1 mutations in
nonsyndromic Wilms’ tumor patients: a UK Children’s Cancer Study
Group Study. J Clin Oncol. 22:4140–4146. 2004.PubMed/NCBI
|
|
27
|
Corbin M, de Reyniès A, Rickman DS, et al:
WNT/β-catenin pathway activation in Wilms tumors: a unifying
mechanism with multiple entries? Genes Chromosomes Cancer.
48:816–827. 2009.
|
|
28
|
Little MH, Williamson KA, Mannens M,
Kelsey A, Gosden C, Hastie ND and van Heyningen V: Evidence that
WT1 mutations in Denys-Drash syndrome patients may act in a
dominant-negative fashion. Hum Mol Genet. 2:259–264. 1993.
|
|
29
|
Royer-Pokora B, Weirich A, Schumacher V,
et al: Clinical relevance of mutations in the Wilms tumor
suppressor 1 gene WT1 and the cadherin-associated protein β1
gene CTNNB1 for patients with Wilms tumors. Results of
long-term surveillance of 71 patients from International Society of
Pediatric Oncology Study 9/Society for Pediatric Oncology. Cancer.
113:1080–1089. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jenkins ZA, van Kogelenberg M, Morgan T,
et al: Germline mutations in WTX cause a sclerosing skeletal
dysplasia but do not predispose to tumorigenesis. Nat Genet.
41:95–100. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Perotti D, Gamba B, Sardella M, et al:
Functional inactivation of the WTX gene is not a frequent
event in Wilms’ tumors. Oncogene. 27:4625–4632. 2008.PubMed/NCBI
|
|
32
|
Wegert J, Wittmann S, Leuschner I,
Geissinger E, Graf N and Gessler M: WTX inactivation is a frequent,
but late event in Wilms tumors without apparent clinical impact.
Genes Chromosomes Cancer. 48:1102–1111. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ruteshouser EC, Robinson SM and Huff V:
Wilms tumor genetics: mutations in WT1, WTX, and
CTNNB1 account for only about one-third of tumors. Genes
Chromosomes Cancer. 47:461–470. 2008.PubMed/NCBI
|
|
34
|
Fukuzawa R, Anaka MR, Weeks RJ, Morison IM
and Reeve AE: Canonical WNT signaling determines lineage
specificity in Wilms tumour. Oncogene. 28:1063–1075. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fukuzawa R, Holman SK, Chow CW,
Savarirayan R, Reeve AE and Robertson SP: WTX mutations can occur
both early and late in the pathogenesis of Wilms tumour. J Med
Genet. 47:791–794. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Haruta M, Arai Y, Watanabe N, et al:
Different incidences of epigenetic but not genetic abnormalities
between Wilms tumors in Japanese and Caucasian children. Cancer
Sci. 103:1129–1135. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Scott RH, Murray A, Baskcomb L, Turnbull
C, et al: Stratification of Wilms tumor by genetic and epigenetic
analysis. Oncotarget. 3:327–335. 2012.PubMed/NCBI
|
|
38
|
Perdu B, Lakeman P, Mortier G, Koenig R,
Lachmeijer A and Van Hul W: Two novel WTX mutations
underscore the unpredictability of male survival in osteopathia
striata with cranial sclerosis. Clin Genet. 80:383–388. 2010.
|
|
39
|
Li CM, Kim CE, Margolin AA, Guo M, et al:
CTNNB1 mutations and overexpression of Wnt/β-catenin target genes
in WT1-mutant Wilm’s tumors. Am J Pathol. 165:1943–1953. 2004.
|
|
40
|
Uschkereit C, Perez N, de Torres C, Küff
M, Mora J and Royer-Pokora B: Different CTNNB1 mutations as
molecular genetic proof for the independent origin of four Wilms
tumours in a patient with a novel germ line WT1 mutation. J
Med Genet. 44:393–396. 2007.
|
